Neurological Complications Associated With Anti–Programmed Death 1 (PD-1) Antibodies

IMPORTANCE: Neurological complications are an increasingly recognized consequence of the use of anti–programmed death 1 (PD-1) antibodies in the treatment of solid-organ tumors, with an estimated frequency of 4.2%. To date, the clinical spectrum and optimum treatment approach are not established. OB...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:JAMA Neurol
Autores principales: Kao, Justin C., Liao, Bing, Markovic, Svetomir N., Klein, Christopher J., Naddaf, Elie, Staff, Nathan P., Liewluck, Teerin, Hammack, Julie E., Sandroni, Paola, Finnes, Heidi, Mauermann, Michelle L.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Medical Association 2017
Materias:
Original Investigation
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5710300/
https://ncbi.nlm.nih.gov/pubmed/28873125
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaneurol.2017.1912
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares